Charles River Laboratories International Company Profile (NYSE:CRL)

About Charles River Laboratories International (NYSE:CRL)

Charles River Laboratories International logoCharles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NYSE:CRL
  • CUSIP: 15986410
  • Web: www.criver.com
Capitalization:
  • Market Cap: $4.78347 billion
  • Outstanding Shares: 47,639,000
Average Prices:
  • 50 Day Moving Avg: $92.20
  • 200 Day Moving Avg: $85.91
  • 52 Week Range: $67.20 - $100.98
P/E:
  • Trailing P/E Ratio: 29.35
  • Foreward P/E Ratio: 17.81
  • P/E Growth: 1.75
Sales & Book Value:
  • Annual Revenue: $1.77 billion
  • Price / Sales: 2.70
  • Book Value: $18.40 per share
  • Price / Book: 5.45
Profitability:
  • EBIDTA: $423.96 million
  • Net Margins: 9.28%
  • Return on Equity: 27.46%
  • Return on Assets: 8.66%
Debt:
  • Debt-to-Equity Ratio: 1.33%
  • Current Ratio: 1.83%
  • Quick Ratio: 1.57%
Misc:
  • Average Volume: 350,034 shs.
  • Beta: 1
  • Short Ratio: 5.63
 

Frequently Asked Questions for Charles River Laboratories International (NYSE:CRL)

What is Charles River Laboratories International's stock symbol?

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

How will Charles River Laboratories International's stock buyback program work?

Charles River Laboratories International declared that its board has approved a stock repurchase plan on Sunday, June 4th 2017, which allows the company to repurchase $150,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company's board of directors believes its stock is undervalued.

How were Charles River Laboratories International's earnings last quarter?

Charles River Laboratories International, Inc. (NYSE:CRL) released its earnings results on Wednesday, May, 10th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.14 by $0.15. The company had revenue of $445.80 million for the quarter, compared to the consensus estimate of $437.04 million. Charles River Laboratories International had a return on equity of 27.46% and a net margin of 9.28%. The firm's quarterly revenue was up 25.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.98 EPS. View Charles River Laboratories International's Earnings History.

When will Charles River Laboratories International make its next earnings announcement?

Charles River Laboratories International is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Charles River Laboratories International.

What guidance has Charles River Laboratories International issued on next quarter's earnings?

Charles River Laboratories International updated its FY17 earnings guidance on Wednesday, May, 10th. The company provided earnings per share (EPS) guidance of $5.00-5.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.06. The company issued revenue guidance of +7.5-9% to ~$1.81-1.83 billion, compared to the consensus revenue estimate of $1.83 billion.

Where is Charles River Laboratories International's stock going? Where will Charles River Laboratories International's stock price be in 2017?

7 brokers have issued 1-year price objectives for Charles River Laboratories International's shares. Their forecasts range from $77.00 to $106.00. On average, they anticipate Charles River Laboratories International's stock price to reach $93.07 in the next year. View Analyst Ratings for Charles River Laboratories International.

What are analysts saying about Charles River Laboratories International stock?

Here are some recent quotes from research analysts about Charles River Laboratories International stock:

  • 1. Jefferies Group LLC analysts commented, "4Q results far outpaced consensus revenue/EPS driven by strength across the 3 segments. Guidance bracketed consensus, lower than us (as expected). We point to margin expansion (with continued price) and capital deployment as upside sources. Strong Discovery and Early Development demand (see our research pointing to funding shifts to Early Dev) should support high single digit organic growth." (2/15/2017)
  • 2. According to Zacks Investment Research, "Charles River Laboratories is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. Charles River is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies and has been in this business for more than 50 years. " (11/4/2016)

Who are some of Charles River Laboratories International's key competitors?

Who are Charles River Laboratories International's key executives?

Charles River Laboratories International's management team includes the folowing people:

  • James C. Foster, Chairman of the Board, President, Chief Executive Officer
  • David R. Smith, Chief Financial Officer, Corporate Executive Vice President
  • David P. Johst, Corporate Executive Vice President - Human Resources, Chief Administrative Officer, General Counsel
  • William D. Barbo, Corporate Executive Vice President and Chief Commercial Officer
  • Davide A. Molho, Corporate Executive Vice President & President, Global Research Models & Services, Safety Assessment and Biologics
  • Michael Gunnar Knell, Corporate Senior Vice President, Chief Accounting Officer
  • George M. Milne Jr., Ph.D., Lead Independent Director
  • Robert J. Bertolini CPA, Independent Director
  • Stephen D. Chubb, Independent Director
  • Deborah Turner Kochevar Ph.D., Independent Director

Who owns Charles River Laboratories International stock?

Charles River Laboratories International's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.63%), BlackRock Inc. (8.12%), FMR LLC (5.25%), Ariel Investments LLC (4.35%), State Street Corp (2.61%) and AQR Capital Management LLC (2.32%). Company insiders that own Charles River Laboratories International stock include C Richard Reese, David P Johst, David Ross Smith, Davide Molho, George M Milne Jr, George Massaro, James C Foster, John J Crowley, Nancy Gillett, Richard F Wallman, Robert J Bertolini, Stephen D Chubb, Thomas F Ackerman and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories International.

Who sold Charles River Laboratories International stock? Who is selling Charles River Laboratories International stock?

Charles River Laboratories International's stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., First Trust Advisors LP, Redmile Group LLC, Monarch Partners Asset Management LLC, Russell Investments Group Ltd., Hodges Capital Management Inc., Putnam FL Investment Management Co. and Chartwell Investment Partners LLC. Company insiders that have sold Charles River Laboratories International stock in the last year include C Richard Reese, David P Johst, David Ross Smith, Davide Molho, George Massaro, James C Foster, Richard F Wallman, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Insider Buying and Selling for Charles River Laboratories International.

Who bought Charles River Laboratories International stock? Who is buying Charles River Laboratories International stock?

Charles River Laboratories International's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Ariel Investments LLC, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Morgan Stanley, Eagle Asset Management Inc. and Vanguard Group Inc.. View Insider Buying and Selling for Charles River Laboratories International.

How do I buy Charles River Laboratories International stock?

Shares of Charles River Laboratories International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Charles River Laboratories International's stock price today?

One share of Charles River Laboratories International stock can currently be purchased for approximately $100.29.


MarketBeat Community Rating for Charles River Laboratories International (NYSE CRL)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  242 (Vote Underperform)
Total Votes:  439
MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Charles River Laboratories International (NYSE:CRL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $93.07 (7.20% downside)

Analysts' Ratings History for Charles River Laboratories International (NYSE:CRL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/14/2017Jefferies Group LLCReiterated RatingBuyLowView Rating Details
6/6/2017Credit Suisse GroupReiterated RatingNeutral$89.00 -> $95.00LowView Rating Details
5/13/2017Barclays PLCSet Price TargetHold$90.00LowView Rating Details
5/11/2017Citigroup Inc.Reiterated RatingNeutral$90.00 -> $104.00LowView Rating Details
1/4/2017Evercore ISIUpgradeHold -> Buy$86.50N/AView Rating Details
12/16/2016Goldman Sachs Group, Inc. (The)UpgradeSell -> Neutral$75.00 -> $77.00N/AView Rating Details
11/18/2016Bank of America CorporationSet Price TargetBuy$93.00N/AView Rating Details
5/22/2016KeyCorpReiterated RatingHold$77.00N/AView Rating Details
4/26/2016GabelliInitiated CoverageBuy$96.00N/AView Rating Details
2/11/2016Deutsche Bank AGReiterated RatingHold$85.00 -> $82.00N/AView Rating Details
1/8/2016Robert W. BairdBoost Price TargetOutperform$86.00 -> $92.00N/AView Rating Details
1/7/2016Wells Fargo & CompanyUpgradeMarket Perform -> OutperformN/AView Rating Details
8/28/2015William BlairReiterated RatingOutperformN/AView Rating Details
7/10/2015Morgan StanleyReiterated RatingEqual Weight$65.00 -> $68.00N/AView Rating Details
(Data available from 6/24/2015 forward)

Earnings

Earnings History for Charles River Laboratories International (NYSE:CRL)
Earnings by Quarter for Charles River Laboratories International (NYSE:CRL)
Earnings History by Quarter for Charles River Laboratories International (NYSE CRL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017        
5/10/2017Q1 2017$1.14$1.29$437.04 million$445.80 millionViewN/AView Earnings Details
2/14/2017Q416$1.11$1.21$441.64 million$466.80 millionViewListenView Earnings Details
11/2/2016Q316$1.13$1.18$291.20 million$425.70 millionViewListenView Earnings Details
8/3/2016Q216$1.10$1.20$425.05 million$434.10 millionViewListenView Earnings Details
5/4/2016Q116$0.90$0.98$354.92 million$354.90 millionViewListenView Earnings Details
2/10/2016Q415$0.94$1.00$349.20 million$353.90 millionViewListenView Earnings Details
11/4/2015Q315$0.94$1.03$340.09 million$349.50 millionViewListenView Earnings Details
7/30/2015Q215$0.97$0.96$338.30 million$339.60 millionViewListenView Earnings Details
4/29/2015Q115$0.82$0.79$324.00 million$320.40 millionViewListenView Earnings Details
2/10/2015Q414$0.71$0.81$318.73 million$329.50 millionViewListenView Earnings Details
10/29/2014Q314$0.80$0.86$326.70 million$327.60 millionViewListenView Earnings Details
8/6/2014Q214$0.82$0.97$327.96 million$341.18 millionViewListenView Earnings Details
4/30/2014Q114$0.74$0.82$302.08 million$299.40 millionViewListenView Earnings Details
2/12/2014Q413$0.68$0.73$289.56 million$289.20 millionViewListenView Earnings Details
10/30/2013Q313$0.70$0.79$290.28 million$292.10 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.71$0.73$293.77 million$294.40 millionViewListenView Earnings Details
5/1/2013Q1 2013$0.71$0.69$294.53 million$291.20 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.60$0.64$280.81 million$280.10 millionViewListenView Earnings Details
10/30/2012$0.62$0.65ViewN/AView Earnings Details
8/7/2012$0.66$0.75ViewN/AView Earnings Details
5/2/2012$0.65$0.70ViewN/AView Earnings Details
2/13/2012$0.56$0.69ViewN/AView Earnings Details
11/1/2011$0.58$0.57ViewN/AView Earnings Details
8/2/2011$0.60$0.70ViewN/AView Earnings Details
5/3/2011$0.55$0.61ViewN/AView Earnings Details
2/8/2011$0.50$0.60ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Charles River Laboratories International (NYSE:CRL)
2017 EPS Consensus Estimate: $4.94
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175$1.07$1.16$1.13
Q2 20175$1.21$1.29$1.23
Q3 20175$1.25$1.26$1.25
Q4 20175$1.31$1.35$1.33
Q1 20181$1.35$1.35$1.35
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Charles River Laboratories International (NYSE:CRL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Charles River Laboratories International (NYSE:CRL)
Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 98.06%
Insider Trades by Quarter for Charles River Laboratories International (NYSE:CRL)
Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)
Insider Trades by Quarter for Charles River Laboratories International (NYSE:CRL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/22/2017Davide MolhoInsiderSell10,948$100.00$1,094,800.00View SEC Filing  
6/22/2017James C FosterChairmanSell43,154$100.00$4,315,400.00View SEC Filing  
6/8/2017David Ross SmithInsiderSell945$95.00$89,775.00View SEC Filing  
5/26/2017Davide MolhoInsiderSell10,976$92.84$1,019,011.84View SEC Filing  
5/12/2017George MassaroDirectorSell1,130$88.30$99,779.00View SEC Filing  
3/16/2017Davide MolhoInsiderSell11,717$90.00$1,054,530.00View SEC Filing  
3/10/2017David P JohstInsiderSell34,593$89.06$3,080,852.58View SEC Filing  
3/6/2017William D BarboInsiderSell1,900$87.90$167,010.00View SEC Filing  
3/3/2017David Ross SmithEVPSell3,890$88.12$342,786.80View SEC Filing  
3/1/2017Robert J BertoliniDirectorSell5,255$87.53$459,970.15View SEC Filing  
2/28/2017James C FosterChairmanSell4,910$87.09$427,611.90View SEC Filing  
2/22/2017James C FosterChairmanSell9,717$87.64$851,597.88View SEC Filing  
1/30/2017David P JohstInsiderSell13,950$78.00$1,088,100.00View SEC Filing  
12/2/2016Stephen D ChubbDirectorSell4,564$71.57$326,645.48View SEC Filing  
11/28/2016C Richard ReeseDirectorSell4,539$71.93$326,490.27View SEC Filing  
8/30/2016Davide MolhoInsiderSell7,877$84.10$662,455.70View SEC Filing  
8/5/2016James C FosterChairmanSell18,351$85.63$1,571,396.13View SEC Filing  
7/29/2016Richard F WallmanDirectorSell7,740$88.00$681,120.00View SEC Filing  
7/1/2016George MassaroDirectorSell3,740$83.09$310,756.60View SEC Filing  
5/24/2016John J CrowleyCAOSell1,913$85.00$162,605.00View SEC Filing  
5/13/2016Richard F WallmanDirectorSell1,970$82.32$162,170.40View SEC Filing  
5/10/2016Richard F WallmanDirectorSell11,990$84.00$1,007,160.00View SEC Filing  
5/9/2016George MassaroDirectorSell985$82.17$80,937.45View SEC Filing  
5/6/2016Richard F WallmanDirectorSell2,720$81.00$220,320.00View SEC Filing  
4/6/2016Davide MolhoVPSell30,667$80.00$2,453,360.00View SEC Filing  
3/2/2016Nancy GillettVPSell7,015$75.00$526,125.00View SEC Filing  
2/29/2016Nancy GillettVPSell3,646$73.50$267,981.00View SEC Filing  
2/25/2016David P JohstVPSell34,075$73.02$2,488,156.50View SEC Filing  
2/24/2016James C FosterCEOSell3,873$70.40$272,659.20View SEC Filing  
2/23/2016George M Milne JrDirectorSell10,440$73.02$762,328.80View SEC Filing  
2/22/2016James C FosterCEOSell9,831$73.12$718,842.72View SEC Filing  
2/12/2016C Richard ReeseDirectorSell4,228$71.48$302,217.44View SEC Filing  
2/12/2016Nancy GillettVPSell6,750$71.90$485,325.00View SEC Filing  
2/1/2016Stephen D ChubbDirectorSell2,000$74.76$149,520.00View SEC Filing  
12/17/2015George MassaroDirectorSell7,740$80.00$619,200.00View SEC Filing  
12/17/2015Thomas F. AckermaninsiderSell10,000$80.00$800,000.00View SEC Filing  
11/19/2015Thomas F. AckermaninsiderSell10,000$75.00$750,000.00View SEC Filing  
11/4/2015Thomas F. AckermaninsiderSell21,612$70.01$1,513,056.12View SEC Filing  
11/2/2015Stephen D ChubbDirectorSell2,000$66.57$133,140.00View SEC Filing  
8/17/2015Thomas F AckermanInsiderSell5,000$75.53$377,650.00View SEC Filing  
5/15/2015Thomas F AckermanCFOSell3,900$70.51$274,989.00View SEC Filing  
5/7/2015George MassaroDirectorSell1,360$70.21$95,485.60View SEC Filing  
3/3/2015Stephen D ChubbDirectorSell2,000$75.52$151,040.00View SEC Filing  
3/2/2015Deborah Turner KochevarDirectorSell2,600$76.59$199,134.00View SEC Filing  
3/2/2015James C FosterCEOSell2,036$76.93$156,629.48View SEC Filing  
3/2/2015Nancy GillettVPSell4,379$76.72$335,956.88View SEC Filing  
2/27/2015Nancy GillettVPSell2,772$76.95$213,305.40View SEC Filing  
2/25/2015James C FosterCEOSell4,621$75.96$351,011.16View SEC Filing  
2/25/2015Nancy GillettVPSell5,015$76.12$381,741.80View SEC Filing  
2/24/2015James C FosterCEOSell4,800$75.70$363,360.00View SEC Filing  
2/24/2015Jorg GellerVPSell12,061$76.17$918,686.37View SEC Filing  
2/23/2015James C FosterCEOSell8,423$76.56$644,864.88View SEC Filing  
2/23/2015Jorg GellerVPSell7,041$76.59$539,270.19View SEC Filing  
2/20/2015George M Milne JrDirectorSell6,000$75.87$455,220.00View SEC Filing  
2/19/2015James C FosterCEOSell9,671$75.00$725,325.00View SEC Filing  
2/18/2015Stephen D ChubbDirectorSell5,011$73.97$370,663.67View SEC Filing  
2/17/2015Jorg GellerVPSell14,430$73.54$1,061,182.20View SEC Filing  
2/17/2015Thomas F AckermanCFOSell4,400$73.50$323,400.00View SEC Filing  
2/13/2015Davide MolhoVPSell19,075$74.00$1,411,550.00View SEC Filing  
2/12/2015Jorg GellerVPSell8,458$73.68$623,185.44View SEC Filing  
1/26/2015Thomas F AckermanCFOSell10,000$70.00$700,000.00View SEC Filing  
1/8/2015David P JohstVPSell4,737$67.00$317,379.00View SEC Filing  
1/7/2015David P JohstVPSell26,100$65.00$1,696,500.00View SEC Filing  
12/1/2014Stephen D ChubbDirectorSell2,000$64.44$128,880.00View SEC Filing  
11/28/2014David P JohstVPSell6,982$65.34$456,203.88View SEC Filing  
11/17/2014Thomas F AckermanCFOSell10,000$63.70$637,000.00View SEC Filing  
11/14/2014Jorg GellerVPSell5,610$63.57$356,627.70View SEC Filing  
11/6/2014C Richard ReeseDirectorSell5,849$63.39$370,768.11View SEC Filing  
11/4/2014John J CrowleyCAOSell1,000$64.00$64,000.00View SEC Filing  
11/3/2014Davide MolhoVPSell16,402$64.54$1,058,585.08View SEC Filing  
11/3/2014George MassaroDirectorSell16,710$65.00$1,086,150.00View SEC Filing  
11/3/2014Thomas F AckermanCFOSell36,100$65.00$2,346,500.00View SEC Filing  
10/30/2014Nancy GillettVPSell1,069$65.00$69,485.00View SEC Filing  
10/28/2014David P JohstVPSell74,780$64.00$4,785,920.00View SEC Filing  
10/3/2014James C FosterCEOSell136,647$62.00$8,472,114.00View SEC Filing  
9/29/2014Thomas F AckermanCFOSell5,000$60.00$300,000.00View SEC Filing  
9/4/2014Davide MolhoVPSell4,900$61.34$300,566.00View SEC Filing  
9/2/2014Stephen D ChubbDirectorSell2,000$59.18$118,360.00View SEC Filing  
8/26/2014George MassaroDirectorSell10,440$60.00$626,400.00View SEC Filing  
8/18/2014Thomas F AckermanCFOSell23,156$59.25$1,371,993.00View SEC Filing  
8/12/2014Richard F WallmanDirectorSell3,240$58.20$188,568.00View SEC Filing  
6/2/2014Stephen D ChubbDirectorSell2,000$52.93$105,860.00View SEC Filing  
5/22/2014Deborah Turner KochevarDirectorSell3,100$53.30$165,230.00View SEC Filing  
5/8/2014George MassaroDirectorSell1,620$52.70$85,374.00View SEC Filing  
5/5/2014Thomas AckermanCFOSell5,430$50.76$275,626.80View SEC Filing  
3/7/2014Nancy GillettVPSell10,110$58.36$590,019.60View SEC Filing  
3/4/2014Nancy GillettVPSell13,650$58.98$805,077.00View SEC Filing  
3/3/2014Stephen ChubbDirectorSell2,000$58.70$117,400.00View SEC Filing  
2/28/2014Jorg GellerVPSell7,486$59.41$444,743.26View SEC Filing  
2/27/2014Nancy GillettVPSell4,000$60.00$240,000.00View SEC Filing  
2/25/2014Jorg GellerVPSell3,188$58.49$186,466.12View SEC Filing  
2/20/2014Nancy GillettVPSell4,000$58.96$235,840.00View SEC Filing  
2/19/2014Stephen ChubbDirectorSell5,198$58.35$303,303.30View SEC Filing  
2/18/2014Thomas AckermanCFOSell14,000$58.05$812,700.00View SEC Filing  
1/13/2014David JohstVPSell19,750$58.00$1,145,500.00View SEC Filing  
1/7/2014George MassaroDirectorSell5,750$54.00$310,500.00View SEC Filing  
12/20/2013Thomas AckermanCFOSell5,000$52.72$263,600.00View SEC Filing  
12/4/2013Jorg GellerVPSell7,200$51.93$373,896.00View SEC Filing  
12/2/2013Stephen ChubbDirectorSell2,000$51.92$103,840.00View SEC Filing  
9/16/2013George MassaroDirectorSell5,958$47.38$282,290.04View SEC Filing  
9/9/2013James C FosterCEOSell174,479$47.00$8,200,513.00View SEC Filing  
9/4/2013Thomas F AckermanCFOSell6,100$46.13$281,393.00View SEC Filing  
9/3/2013Stephen ChubbDirectorSell2,000$46.49$92,980.00View SEC Filing  
8/29/2013James FosterCEOSell40,983$47.00$1,926,201.00View SEC Filing  
8/22/2013Davide MolhoVPSell6,500$47.93$311,545.00View SEC Filing  
8/20/2013Stephen ChubbDirectorSell4,000$47.46$189,840.00View SEC Filing  
8/5/2013Jorg GellerVPSell3,025$46.38$140,299.50View SEC Filing  
8/5/2013Richard WallmanDirectorSell1,500$45.95$68,925.00View SEC Filing  
8/2/2013Davide MolhoVPSell4,100$45.89$188,149.00View SEC Filing  
8/2/2013Deborah Turner KochevarDirectorSell4,447$46.02$204,650.94View SEC Filing  
8/2/2013Thomas AckermanCFOSell26,250$46.03$1,208,287.50View SEC Filing  
6/3/2013Thomas F AckermanCFOSell4,000$42.40$169,600.00View SEC Filing  
5/14/2013James C FosterCEOSell113,810$45.00$5,121,450.00View SEC Filing  
5/10/2013George MassaroDirectorSell2,020$44.09$89,061.80View SEC Filing  
3/13/2013David P JohstVPSell17,038$45.00$766,710.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Charles River Laboratories International (NYSE:CRL)
Latest Headlines for Charles River Laboratories International (NYSE:CRL)
Source:
DateHeadline
americanbankingnews.com logoCharles River Laboratories International, Inc. (CRL) Chairman James C. Foster Sells 43,154 Shares
www.americanbankingnews.com - June 23 at 5:02 PM
americanbankingnews.com logoDavide Molho Sells 10,948 Shares of Charles River Laboratories International, Inc. (CRL) Stock
www.americanbankingnews.com - June 23 at 1:35 PM
americanbankingnews.com logo$1.22 Earnings Per Share Expected for Charles River Laboratories International, Inc. (CRL) This Quarter
www.americanbankingnews.com - June 23 at 7:58 AM
americanbankingnews.com logoCharles River Laboratories International, Inc. (CRL) Upgraded to Strong-Buy by BidaskClub
www.americanbankingnews.com - June 20 at 8:44 PM
americanbankingnews.com logoCharles River Laboratories International, Inc. (CRL) Receives "Buy" Rating from Jefferies Group LLC
www.americanbankingnews.com - June 14 at 7:56 AM
americanbankingnews.com logoInsider Selling: Charles River Laboratories Intl. Inc (CRL) Insider Sells 945 Shares of Stock
www.americanbankingnews.com - June 9 at 1:34 PM
americanbankingnews.com logoCharles River Laboratories Intl. Inc (CRL) to Post Q2 2017 Earnings of $1.23 Per Share, First Analysis Forecasts
www.americanbankingnews.com - June 7 at 8:16 AM
americanbankingnews.com logoCharles River Laboratories Intl. Inc (CRL) Earns "Neutral" Rating from Credit Suisse Group AG
www.americanbankingnews.com - June 6 at 3:36 PM
americanbankingnews.com logoCharles River Laboratories Intl. Inc (CRL) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 6 at 10:33 AM
finance.yahoo.com logoCharles River Laboratories to Present at Jefferies Global Healthcare Conference
finance.yahoo.com - June 5 at 9:32 PM
americanbankingnews.com logoCharles River Laboratories Intl. (CRL) to Repurchase $150.00 million in Outstanding Shares
www.americanbankingnews.com - June 4 at 11:28 AM
finance.yahoo.com logoETFs with exposure to Charles River Laboratories International, Inc. : June 1, 2017
finance.yahoo.com - June 1 at 5:08 PM
americanbankingnews.com logo$460.02 Million in Sales Expected for Charles River Laboratories Intl. Inc (CRL) This Quarter
www.americanbankingnews.com - June 1 at 1:20 PM
americanbankingnews.com logoDavide Molho Sells 10,976 Shares of Charles River Laboratories Intl. Inc (CRL) Stock
www.americanbankingnews.com - May 31 at 7:28 AM
finanznachrichten.de logoEisai and Charles River Laboratories Announce Extension of Integrated Drug Discovery Partnership
www.finanznachrichten.de - May 30 at 4:28 PM
americanbankingnews.com logo$1.23 Earnings Per Share Expected for Charles River Laboratories Intl. Inc (CRL) This Quarter
www.americanbankingnews.com - May 30 at 9:58 AM
finance.yahoo.com logoCharles River Labs Re-Enters Buy Zone; Gets Stock Rating Upgrade
finance.yahoo.com - May 25 at 6:03 PM
finance.yahoo.com logoToday's Bell Ringer, May 23, 2017
finance.yahoo.com - May 23 at 12:41 PM
finance.yahoo.com logoOpening Bell, May 23, 2017
finance.yahoo.com - May 23 at 12:41 PM
seekingalpha.com logoCharles River Laboratories International (CRL) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow
seekingalpha.com - May 22 at 4:19 PM
finance.yahoo.com logoETFs with exposure to Charles River Laboratories International, Inc. : May 16, 2017
finance.yahoo.com - May 16 at 4:30 PM
finance.yahoo.com logoCharles River Laboratories Announces Updates to Oncology Business
finance.yahoo.com - May 16 at 12:15 PM
americanbankingnews.com logoGeorge Massaro Sells 1,130 Shares of Charles River Laboratories Intl. Inc (CRL) Stock
www.americanbankingnews.com - May 15 at 4:22 PM
finance.yahoo.com logoCharles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 15, 2017
finance.yahoo.com - May 15 at 12:02 PM
americanbankingnews.com logoFY2017 Earnings Forecast for Charles River Laboratories Intl. Inc (CRL) Issued By William Blair
www.americanbankingnews.com - May 15 at 8:48 AM
americanbankingnews.com logoFY2017 EPS Estimates for Charles River Laboratories Intl. Inc Increased by Analyst (CRL)
www.americanbankingnews.com - May 15 at 8:48 AM
americanbankingnews.com logoCharles River Laboratories Intl. Inc Expected to Post FY2017 Earnings of $5.09 Per Share (CRL)
www.americanbankingnews.com - May 15 at 8:48 AM
americanbankingnews.com logoQ2 2017 Earnings Estimate for Charles River Laboratories Intl. Inc (CRL) Issued By SunTrust Banks
www.americanbankingnews.com - May 15 at 7:58 AM
americanbankingnews.com logoBarclays PLC Analysts Give Charles River Laboratories Intl. Inc (CRL) a $90.00 Price Target
www.americanbankingnews.com - May 15 at 12:34 AM
americanbankingnews.com logoGabelli Weighs in on Charles River Laboratories Intl. Inc's FY2021 Earnings (CRL)
www.americanbankingnews.com - May 12 at 6:56 PM
finance.yahoo.com logoCharles River Laboratories International, Inc. breached its 50 day moving average in a Bearish Manner : CRL-US : May 12, 2017
finance.yahoo.com - May 12 at 5:02 PM
finance.yahoo.com logo​Charles River shareholders reject PETA proposal on monkey research
finance.yahoo.com - May 12 at 5:02 PM
americanbankingnews.com logoCharles River Laboratories Intl. Inc (CRL) to Post Q2 2017 Earnings of $1.21 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 12 at 10:40 AM
americanbankingnews.com logoQ2 2017 Earnings Forecast for Charles River Laboratories Intl. Inc (CRL) Issued By William Blair
www.americanbankingnews.com - May 12 at 10:40 AM
americanbankingnews.com logoCharles River Laboratories Intl. Inc (CRL) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 12 at 10:37 AM
americanbankingnews.com logoJefferies Group LLC Reaffirms "Buy" Rating for Charles River Laboratories Intl. Inc (CRL)
www.americanbankingnews.com - May 11 at 8:32 PM
americanbankingnews.com logoCharles River Laboratories Intl.'s (CRL) Neutral Rating Reaffirmed at Citigroup Inc
www.americanbankingnews.com - May 11 at 8:32 PM
finance.yahoo.com logoEdited Transcript of CRL earnings conference call or presentation 10-May-17 12:30pm GMT
finance.yahoo.com - May 10 at 9:43 PM
seekingalpha.com logoCharles River Laboratories International (CRL) Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 4:40 PM
americanbankingnews.com logoCharles River Laboratories Intl. Inc (CRL) Releases Earnings Results
www.americanbankingnews.com - May 10 at 2:26 PM
americanbankingnews.com logoCharles River Laboratories Intl. Inc (CRL) Releases FY17 Earnings Guidance
www.americanbankingnews.com - May 10 at 9:02 AM
finance.yahoo.com logoCharles River Laboratories Announces First-Quarter 2017 Results from Continuing Operations
finance.yahoo.com - May 10 at 8:09 AM
marketbeat.com logoCharles River beats Street 1Q forecasts
marketbeat.com - May 10 at 7:28 AM
americanbankingnews.com logo$438.08 Million in Sales Expected for Charles River Laboratories Intl. Inc (CRL) This Quarter
www.americanbankingnews.com - May 6 at 9:27 AM
finance.yahoo.com logo4 Medical Stocks That Could Be Big Winners Next Week
finance.yahoo.com - May 5 at 9:44 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Charles River Laboratories Intl. Inc (CRL) Will Announce Earnings of $1.14 Per Share
www.americanbankingnews.com - May 4 at 11:23 AM
americanbankingnews.com logoCharles River Laboratories Intl. (CRL) Receiving Somewhat Critical Media Coverage, Report Finds
www.americanbankingnews.com - May 1 at 4:30 PM
americanbankingnews.com logoSomewhat Favorable Press Coverage Very Unlikely to Impact Charles River Laboratories Intl. (CRL) Stock Price
www.americanbankingnews.com - April 28 at 10:14 PM
finance.yahoo.com logoCharles River Laboratories International, Inc. breached its 50 day moving average in a Bearish Manner : CRL-US : April 26, 2017
finance.yahoo.com - April 27 at 2:11 AM
americanbankingnews.com logoCharles River Laboratories Intl. (CRL) Receiving Somewhat Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 25 at 5:14 PM

Social

Chart

Charles River Laboratories International (CRL) Chart for Saturday, June, 24, 2017

This page was last updated on 6/24/2017 by MarketBeat.com Staff